Furue S, Hori Y, Kuwabara K, Ikeuchi J, Onoyama H, Yamamoto M, Tanaka K
Discovery Research Laboratories II, Shionogi & Co. Ltd, Osaka, Japan.
Gut. 1997 Dec;41(6):826-31. doi: 10.1136/gut.41.6.826.
Two different types of secretory phospholipase A2 (PLA2), pancreatic group I (PLA2-I) and non-pancreatic group II (PLA2-II), have been identified and postulated to be associated with the pathogenesis of various diseases, such as acute pancreatitis, septic shock, and multiple organ failure.
To investigate the type of secretory PLA2 responsible for its catalytic activity found in plasma and ascites of experimental acute pancreatitis.
Acute pancreatitis of differing severity was induced by the injection of different concentrations (1% or 10%) of sodium deoxycholate (DCA) into the common biliopancreatic duct in rats, and catalytic PLA2 activity in plasma and ascites were differentiated by anti-PLA2-I antibody and specific inhibitor of PLA2-II. Survival rate and plasma amylase, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were also measured.
In 1% and 10% DCA induced acute pancreatitis, plasma amylase values as well as PLA2 activity in ascites were greatly increased. PLA2 activity in plasma was also notably increased in 10% DCA induced acute pancreatitis, but not in 1% DCA induced acute pancreatitis. PLA2-I specific polyclonal antibody significantly inhibited PLA2 activity in ascites but not that in plasma. In contrast, plasma PLA2 activity was completely suppressed by PLA2-II specific inhibitor. In addition, a high mortality (93% at five hours) and a significant increase in plasma AST and ALT were noted in 10% DCA induced pancreatitis.
Ascites PLA2 activity is mainly derived from PLA2-I, whereas plasma PLA2 activity is mostly derived from PLA2-II in severe acute pancreatitis, suggesting that increased plasma PLA2-II activity might be implicated in hepatic failure arising after severe acute pancreatitis.
已鉴定出两种不同类型的分泌型磷脂酶A2(PLA2),即胰腺I型(PLA2-I)和非胰腺II型(PLA2-II),并推测它们与多种疾病的发病机制有关,如急性胰腺炎、感染性休克和多器官功能衰竭。
研究在实验性急性胰腺炎的血浆和腹水中发现的具有催化活性的分泌型PLA2的类型。
通过向大鼠胆总管内注射不同浓度(1%或10%)的脱氧胆酸钠(DCA)诱导不同严重程度的急性胰腺炎,并用抗PLA2-I抗体和PLA2-II特异性抑制剂区分血浆和腹水中的催化PLA2活性。还测量了存活率以及血浆淀粉酶、天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)。
在1%和10% DCA诱导的急性胰腺炎中,腹水的血浆淀粉酶值和PLA2活性均大幅增加。在10% DCA诱导的急性胰腺炎中血浆PLA2活性也显著增加,但在1% DCA诱导的急性胰腺炎中未增加。PLA2-I特异性多克隆抗体显著抑制腹水中的PLA2活性,但不抑制血浆中的PLA2活性。相反,血浆PLA2活性被PLA2-II特异性抑制剂完全抑制。此外,在10% DCA诱导的胰腺炎中观察到高死亡率(5小时时为93%)以及血浆AST和ALT显著升高。
在重症急性胰腺炎中,腹水PLA2活性主要来源于PLA2-I,而血浆PLA2活性主要来源于PLA2-II,这表明血浆PLA2-II活性增加可能与重症急性胰腺炎后发生的肝衰竭有关。